<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )*
Novatek International, Inc.
-------------------------------------------
(Name of Issuer)
Common
-------------------------------------------
(Title of Class of Securities)
669932 501
-------------------------------------------
(CUSIP Number)
Vincent D. Celentano
987 Hillsboro Mile
Hillsboro Bch, Fl 33062
(954) 786-0150
-------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 5, 1996
-------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Check the following box if a fee is being paid with the statement [ ]. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of the five percent or less of such
class.) (See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities and Exchange Act
of 1934 ("Act") or otherwise subject to the liabilities of that section or the
Act but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
<PAGE>
CUSIP NO. 669932 501 Page 2 of 4 Pages
1. NAME OF REPORTING PERSON
Celantano Limited Partnership
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a)[ ]
(b)[ ]
3. SEC USE ONLY
4. SOURCE OF FUNDS*
0
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e)
[ ]
6. CITIZENSHIP OR PLACE OR ORGANIZATION
New Hampshire
7. SOLE VOTING POWER
(see 2 of 5)
NUMBER OF 2,002,638 Shares common - vote cast by General Partner
SHARES 8. SHARED VOTING POWER
BENEFICIALLY
OWNED BY 9. SOLE DISPOSITIVE POWER
EACH
REPORTING PERSON 10. SHARED DISPOSITIVE POWER
WITH
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,002,638 Shares Common Stock
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES*
[ ]
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
14. TYPE OF REPORTING PERSON*
PN
<PAGE>
<PAGE>
CUSIP NO. 669932 501 Page 3 of 4 Pages
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Response to Items 1 through 7:
Item 1. Security and Issuer
Class: Common Stock
Name: Novatek International, Inc.
Address: 1401 Neptune Drive
Boyton Beach, FL 33426
Item 2. Identity and Background
(a)- (c):
Shareholder is: Celentano Limited Partnership
a New Hampshire Partnership
Statutory Agent: CT Corporation
9 Capitol St., Concord, NH 03301
Business mailing address see below.
The Limited Partners are: The Trust for David W. Celentano
The Trust for Vincent L. Celentano
The Trust for William D. Celentano
The General Partner is: Middlebury Enterprises, Inc.
a New Hampshire Partnership
Vincent D. Celentano, Sole Shareholder
Sole Officer, & Sole Director
Principal Activity of
Partnership: Investments
Mailing address of the
above: 987 Hillsboro Mile
Hillsboro Beach, Florida 33062
(d) N/A
(e) N/A
(f) USA
Item 3. Source and Amount of Funds or Other Considerations
Medical Products, Inc. a Florida Corporation merged with Novatek International
Holdings, Inc., A Florida Corporation, wholly owned by Novatek International
Inc. Celentano Limited Partnership held a 50% stock interest in Medical
Products, Inc. Novatek International Holdings, Inc. exchanged stock with the
Celentano Limited Partnership for Medical Products, Inc. stock.
<PAGE>
<PAGE>
CUSIP NO. 669932 501 Page 4 of 4 Pages
Item 4. Purpose of Transaction
(a) N/A
(b) N/A
(c) There has been a discussion wherein it might be in the best
interests of the Company to review its construction business activities , and
then; expand profitable construction business and sell unprofitable business.
(d) N/A
(e) N/A
(f) N/A
(g) N/A
(h) N/A
(i) N/A
(j) N/A
Item 5. Interest in Securities of the Issuer
(a) Celantano Limited Partnership owns 2,002,638 shares of Common
Stock (16.5% at the time of issue)
(b) Middlebury Enterprises, Inc. has the sole power to vote the
2,002,638 shares of Common Stock. Vincent D. Celentano is president, sole
shareholder and sole director of Middlebury Enterprises, Inc.
(c) None
(d) N/A
(e) N/A.
Item 6. Contracts, Arrangements, Understandings or Relationships With Respect
to Securities of the Issuer
N/A
Item 7. Material to be Filed as Exhibits
N/A
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief,
the reporting person certifies that the information set forth in the Statement
is true, complete and correct.
Dated: July 23, 1996
By Celentano Limited Partnership
Middletbury Enterprises, Inc
/s/ Vincent D. Celantano
----------------------------------
President & General Partner
